Skip to content
OpenCapital
Get started

Enovis ENOV Reconstructive — Research and development expense

Other segment segments

Prevention & Recovery
$7.75M—

Similar metrics at other companies

IAR
IARTTissue Reconstruction — R&D
$7.53M+26.1%
Bausch + Lomb logo
BLCOSurgical — R&D
$13M+18.2%
OSI Systems logo
OSISHealthcare Division — Research And Development Expense
$4.63M+7.7%
QuidelOrtho Corporation logo
QDELR&D
$2.3M-14.8%
HTF
HTFLResearch And Development Expense Other Than Regulatory And Clinical Expense
$9.67M+48.8%
Babcock & Wilcox Enterprises logo
BWResearch and development costs
$803K+131%

Other financials

Income statement

See full
Revenue$589.2M+5.4%
Gross profit$365.5M+10.0%
Operating income$6.5M+114%
Net income-$8.8M+84.3%
EPS (diluted)-$0.15+84.7%

Balance sheet

See full
Cash & equivalents$33.1M-13.9%
Total debt$1.4B-3.1%
Total equity$1.5B-43.6%
Total assets$3.8B-21.4%

Cash flow

See full
Operating cash flow$24.0M+1,601%
CapEx$52.8M+22.1%
Free cash flow-$28.9M+35.7%

Valuation

See full
Market cap$1.23B-28.4%
Enterprise value$2.55B-17.1%
P/S0.5×-0.3×

Profitability

See full
Gross margin60.5%+4.0pp
Operating margin-47%+18.6pp
Net margin-49.9%+24.1pp
FCF margin-3.1%-1.1pp

Returns & leverage

See full
Return on equity-55.5%-1,722pp
Debt / equity0.9×+0.4×
Current ratio2×-0.5×

Where this comes from

Reported directly by Enovis in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Enovis’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Enovis's reconstructive — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Enovis's reconstructive — research and development expense?
Enovis (ENOV) reported reconstructive — research and development expense of $23.79M in Q1 2026.
How has Enovis's reconstructive — research and development expense changed year-over-year?
Enovis's reconstructive — research and development expense increased by 23.3% year-over-year, from $19.29M to $23.79M.
What is the long-term trend for Enovis's reconstructive — research and development expense?
Over 3 years (2022 to 2025), Enovis's reconstructive — research and development expense has grown at a 44.9% compound annual growth rate (CAGR), from $27.36M to $83.27M.
What does reconstructive — research and development expense mean?
Expenditures dedicated to the innovation, design, and clinical testing of new reconstructive surgical solutions and technologies. This metric reflects the company's commitment to long-term product pipeline development and maintaining a competitive edge in clinical outcomes.